Resyca and Cyrano Therapeutics announce positive Phase 2 FLAVOR clinical trial data demonstrating the significant potential of CYR-064 delivered through soft mist nasal technology as a treatment for persistent post-viral loss of smell
Enschede, Netherlands, October 22, 2026 – Resyca®, a leading innovator in soft mist inhaler and soft nasal spray technologies, and Cyrano Therapeutics, a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, have announced the clinical validation of Cyrano Therapeutics’ lead therapy, CYR-064, delivered using Resyca’s proprietary soft mist nasal spray technology, for persistent post-viral loss of smell (hyposmia), with the positive results from the Phase 2 FLAVOR clinical trial.
Published, in vitro work using Resyca’s proprietary soft mist nasal spray technology demonstrated that the uniform, micron-sized droplets it produces, delivered as a soft mist, deposits more drug on the olfactory cleft than a conventional spray, validating its consistent and targeted drug distribution within the nasal cavity. Specific to the FLAVOR clinical trial, Resyca’s soft mist technology, integrated into Aeropump’s spray pump system, generates a low spray velocity soft mist with a narrow, controlled droplet-size distribution, enabling improved deposition of CYR-064 in the target olfactory region, thereby increasing the opportunity for therapeutic efficacy. Earlier trials used irrigation or oral dosing for drug delivery.
Phase 2 of the FLAVOR programme enrolled 151 patients in a randomised, double-blind, placebo-controlled study across 14 clinical sites in the U.S. The study met its primary safety endpoint and demonstrated statistically significant improvements across two independent measures of smell function, with continued improvement through the end of the 24-week study.
The positive Phase 2 FLAVOR results highlight the important role that delivery technology can play in enabling advanced nasal therapies. Beyond smell loss, targeted delivery to the olfactory region has relevance to other applications such as nose-to-brain delivery. Cyrano Therapeutics FLAVOR trial represents an important clinical validation of Resyca’s soft mist technology as part of a drug-device combination product under active development.
Deborah Jones, CEO, Resyca said: “The FLAVOR results reinforce the importance of delivery technology in unlocking the potential of advanced nasal therapies. Our soft mist technology is designed to enhance targeted deposition in the olfactory region through low-velocity and tightly controlled droplet-size distribution. Seeing our technology successfully incorporated into a clinical stage drug-device combination program for nasal drug delivery is an important milestone for Resyca and highlights its potential value across a range of future nasal therapeutic applications.
Rick Geoffrion, President and CEO of Cyrano Therapeutics, said: “The strength of the Phase 2 FLAVOR data reinforces our confidence in CYR-064’s potential to treat persistent post-viral smell loss, with statistically significant improvements across two independent measures of smell function in patients under 60 receiving the high dose, alongside a favourable safety profile. Resyca’s core technology and its ability to help deliver CYR-064 in a fine, low-velocity mist to the olfactory region is an important contributor to the encouraging results seen in FLAVOR and a key element of our therapeutic approach as we prepare to advance into Phase 3 development. We look forward to a close, long-lasting relationship between our 2 companies.”
Hyposmia, including post-viral hyposmia, is an increasingly prevalent and serious chronic sensory condition for which there is no approved drug therapy and limited treatment options. The successful completion of Phase 2 in the FLAVOR trial, strengthens the case for CYR-064 potentially becoming the first FDA-approved therapy indicated for the treatment of smell loss. Cyrano Therapeutics and Resyca are committed to bringing this innovative treatment to patients with chemosensory disorders and are excited to continue into Phase 3 development.
About Resyca
Resyca® is redefining drug delivery with its next‑generation Soft Mist Inhalers and Soft Nasal Sprays. Founded in 2020 as a joint venture between Medspray and Bespak, Resyca® develops advanced, proprietary delivery platforms that integrate Medspray’s micro‑nozzle technology.
With Resyca’s® delivery devices, pharmaceutical partners can clearly differentiate their therapies through highly efficient pulmonary delivery and precise nasal administration—making Resyca’s platforms an excellent fit for a broad spectrum of drug–device combination products.
To further accelerate development and commercialization, Resyca supports pharmaceutical partners with a comprehensive suite of services spanning early‑stage development through to full commercial launch.
To learn more, please visit www.resyca.com.
About Cyrano Therapeutics
Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company. Since our foundation, Cyrano has been working diligently to develop therapies for people struggling with the loss of smell and taste.
More information: cyranotherapeutics.com
